Indegene Receives Frost & Sullivan Recognition for AI-Powered Pharma Commercialisation

Manufacturing-News
Image Courtesy: Indegene

Indegene has received Frost & Sullivan’s 2026 Global Enabling Technology Leadership Recognition for its work in artificial intelligence-powered pharmaceutical commercialisation services. The recognition acknowledges the company’s use of AI, life sciences expertise, data and technology to help pharmaceutical organisations improve commercial and medical operations. Frost & Sullivan assessed companies on strategy effectiveness and execution, evaluating how well their approaches address industry requirements and deliver results at scale.

Indegene was recognised for applying AI across commercial, medical, regulatory, safety, analytics, content and field engagement workflows. Its services combine technology platforms, consulting, workflow integration and execution support to help pharmaceutical companies plan, create, review, distribute and optimise commercial and medical content.

Surbhi Gupta, Industry Principal at Frost & Sullivan, said Indegene’s approach combines model-agnostic technology with life sciences expertise, knowledge orchestration and process redesign. She noted that its focus on connected and governed workflows extends beyond individual automation tasks to improve consistency, speed and reliability across pharmaceutical commercialisation.

A central part of Indegene’s approach is its Pharma Operating System (OS), which connects business decisions, workflow execution and intelligence across an organisation. The platform is designed to help pharmaceutical companies move away from fragmented processes towards integrated operating models.

The company also uses Cortex, its life sciences-focused reasoning engine, to help subject matter experts organise specialised knowledge, develop validated knowledge graphs and guide AI-enabled workflows. Applications include regulatory authoring, medical writing, creative content adaptation and medical-legal-regulatory review.

Vivek Ghai, Executive Vice President, Enterprise Commercial Solutions at Indegene, said the next phase of AI adoption would depend on connecting intelligence, decision-making and execution across enterprises. He added that embedding AI into operational processes could help life sciences companies improve decisions, accelerate execution and achieve measurable business outcomes.

Indegene’s services bring together generative AI, data, in-house technology platforms, consulting and operational support. The company focuses on helping pharmaceutical organisations manage complex processes in regulated environments while improving workflow efficiency and consistency.

The recognition comes as pharmaceutical companies explore ways to incorporate AI into operations while maintaining governance and compliance requirements. Indegene works across commercial, medical, research and development, and drug safety functions throughout the product lifecycle.

Indegene Limited (BSE: 544172; NSE: INDGN) provides technology-enabled services to the life sciences industry. The company supports commercial, medical, research and development, and safety operations across the product lifecycle. It combines life sciences expertise with AI-enabled platforms and governed operating models to help pharmaceutical organisations manage complex workflows at scale.